Sotio Biotech

SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until end of 2023.

SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc. (LCB, KOSDAQ: 141080), a biotechnology company focused on developing its clinical-stage platform technology enabling antibody-drug conjugates (ADCs) with an excellent therapeutic index. SOTIO will obtain rights to deploy LCB’s ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens.

SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced new data from the ongoing Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, as a monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors. The data are presented in three posters at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting from November 10-14, 2021.

Index of Cancer Preparedness: The Czech Republic ranks eighth in preparedness for the treatment of cancer

The Czech Republic ranks eighth among 29 countries assessed for the quality of their measures for cancer prevention and treatment. PPF and SOTIO initiated the country’s participation in the Index of Cancer Preparedness (ICP) designed by The Economist Intelligence Unit.

SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics

SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced that it has acquired the rights to Unum Therapeutics’ (Nasdaq: UMRX) BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumors. The proprietary Bolt-on Chimeric Receptor technology incorporates novel transgenes to enhance T cell function in the solid tumor microenvironment.

PPF offered the Czech state 120 tonnes of medical equipment free of charge in the battle against coronavirus

Today morning, PPF Group’s majority shareholder Petr Kellner met with the Prime Minister of the Czech Republic, Andrej Babiš, and Minister of Industry and Trade Jiří Havlíček, at the building of the Office of the Government.

SOTIO opens office in Basel, Switzerland, to accelerate development of its pipeline products

SOTIO, a biotechnology company owned by the PPF Group, announce today the opening of offices of SOTIO Biotech AG at the Technology Park Basel, Switzerland. The SOTIO office will host the clinical development team, as well as other functions to progress its broad clinical development pipeline towards filing for marketing authorization and commercial launch.

PPF and SOTIO invest $6.5 million in MaveriX Oncology and its lead program MVX-5005

SOTIO, together with PPF, and MaveriX Oncology, Inc., today announce the investment of PPF Group in MaveriX Oncology Inc., a private biotech company with a proprietary pipeline of targeted, small-molecule cancer chemo-immunotherapeutics. PPF has committed to investing $6.5 million in MaveriX Oncology’s ongoing Series A financing contingent on key development milestones. In total, MaveriX is aiming to secure a total of $20 million in funding and the round will remain open for additional investors to join. The proceeds will enable MaveriX to advance the company’s lead program MVX-5005 through IND-enabling studies, and complete first-in-human Phase Ia/Ib clinical trials for the treatment of solid tumors in support of clinical proof-of-concept. The company will also advance further platform programs to drug candidate selection.